Quantcast

Ustekinumab in adolescents with moderate to severe plaque psoriasis: a guide to its use

Research paper by Kate McKeage, Katherine A. Lyseng-Williamson

Indexed on: 11 Feb '16Published on: 11 Feb '16Published in: Drugs & therapy perspectives : for rational drug selection and use



Abstract

Ustekinumab (Stelara®), the only approved biological agent that acts as an antagonist of interleukin-12/23, is an effective and generally well tolerated option for the treatment of adolescents with moderate to severe plaque psoriasis. In a phase 3 trial in this patient population, subcutaneous ustekinumab improved symptoms and health-related quality of life, and had a tolerability profile similar to that observed in adults. Based on the results of this trial, the approved indication of ustekinumab in the EU was recently expanded to include the treatment of moderate to severe plaque psoriasis in adolescents aged ≥12 years who are inadequately controlled by or intolerant to other systemic therapies or phototherapies.